Anaplastic lymphoma kinase (ALK) positive nonsmall cell lung cancer (NSCLC) is found in 2% to 7% of patients.[4] Crizotinib is a first small molecule tyrosine kinase inhibitor to ALK, and it has been approved for the first-line treatment of ALK rearranged NSCLC patients. Here, ALK is linked to non-small cell lung carcinoma.